Zhejiang Lianhui Biomedical Technology

Zhejiang Lianhui Biomedical Technology is a clinical-stage biopharmaceutical company headquartered in Huzhou, China, dedicated to the research and development of innovative small molecule drugs. Established in 2018, the company targets significant unmet medical needs in oncology, metabolic diseases, and autoimmune conditions. Its clinical pipeline is led by LH-011, a CDK4/6 inhibitor for breast cancer, and LH-001, a URAT1 inhibitor for the treatment of gout and hyperuricemia. Lianhui Bio utilizes a robust R&D platform to design highly selective molecules with improved safety and efficacy profiles. The company has successfully secured multiple rounds of financing from leading institutional investors to accelerate its clinical programs.